Lilly + Prime Therapeutics Push the Envelope on Next Generation Value-based Agreements
August 12, 2020
Lilly has partnered with Prime Therapeutics to explore how value-based arrangements (VBA’s) can be used to improve patient outcomes while lowering healthcare costs. Lily and Prime will explore VBA’s that include patient-focused value metrics, use value-based insurance design (VBID) to reduce out-of-pocket (OOP) costs for patients, increase access and adherence to medicines, and utilize VBA-enabled data sharing to facilitate more accurate prescribing.
According to Erin Huntington, Lilly senior director, PRA strategy & marketing, “Improvements to VBAs require that the ‘value’ represents value to patients and reflect improvements in meaningful clinical outcomes and quality of life metrics.”
This new partnership seeks to place patient-reported outcomes within success measures, combining them with Prime Therapeutics’ integrated medical and pharmacy data. The next generation VBAs will improve medication access and lower patient costs.
Learn more about how Lilly and Prime Therapeutics are designing the next generation of patient-centric VBAs here.
(Source: Eli Lily and Company, July 28, 2020)
